Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNSNYSE:ENOVNASDAQ:ESTANASDAQ:MYGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAVANOS MEDICAL$12.09-0.4%$12.46$11.75▼$25.36$561.40M1.14376,575 shs593,038 shsENOVEnovis$30.01-0.3%$33.03$28.83▼$49.83$1.72B1.72842,998 shs1.30 million shsESTAEstablishment Labs$36.58-3.3%$34.76$26.56▼$52.41$1.09B0.74472,757 shs292,333 shsMYGNMyriad Genetics$4.86-1.2%$5.49$3.81▼$29.30$453.51M1.841.24 million shs1.28 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAVANOS MEDICAL-0.45%-1.10%-1.83%-14.62%-38.19%ENOVEnovis-0.41%-6.96%-5.07%-23.82%-33.45%ESTAEstablishment Labs-3.25%-5.99%-0.11%-11.98%-11.77%MYGNMyriad Genetics-1.22%-1.22%+24.30%-50.05%-79.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAVANOS MEDICAL1.2828 of 5 stars0.03.00.00.00.01.72.5ENOVEnovis2.9602 of 5 stars3.42.00.00.02.21.71.9ESTAEstablishment Labs2.5038 of 5 stars3.42.00.00.02.22.50.6MYGNMyriad Genetics4.065 of 5 stars4.11.00.04.12.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAVANOS MEDICAL 0.00N/AN/AN/AENOVEnovis 2.80Moderate Buy$58.0093.29% UpsideESTAEstablishment Labs 2.80Moderate Buy$52.4043.25% UpsideMYGNMyriad Genetics 2.13Hold$14.38195.98% UpsideCurrent Analyst Ratings BreakdownLatest ESTA, AVNS, ENOV, and MYGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.005/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/16/2025ESTAEstablishment LabsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$62.005/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/14/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$48.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/8/2025MYGNMyriad GeneticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/7/2025MYGNMyriad GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$18.005/7/2025MYGNMyriad GeneticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAVANOS MEDICAL$687.80M0.81$11.85 per share1.02$18.03 per share0.67ENOVEnovis$2.11B0.81$19.11 per share1.57$45.10 per share0.67ESTAEstablishment Labs$170.24M6.21N/AN/A$1.90 per share19.25MYGNMyriad Genetics$837.60M0.53$0.99 per share4.92$7.70 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAVANOS MEDICAL-$392.10M-$8.37N/A6.99N/A-55.80%6.26%4.63%7/30/2025 (Estimated)ENOVEnovis-$825.49M-$13.95N/A9.41N/A-37.65%5.99%3.44%8/6/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.10N/AN/AN/A-52.34%-196.25%-26.64%8/5/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)Latest ESTA, AVNS, ENOV, and MYGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/7/2025Q1 2025ESTAEstablishment Labs-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 million5/6/2025Q1 2025AVNSAVANOS MEDICAL$0.19$0.26+$0.07$0.14$161.75 million$167.50 million5/6/2025Q1 2025MYGNMyriad Genetics-$0.05-$0.03+$0.02N/A$200.37 million$195.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAVANOS MEDICALN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAVANOS MEDICAL0.122.571.56ENOVEnovis0.522.551.32ESTAEstablishment Labs5.723.362.05MYGNMyriad Genetics0.081.901.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAVANOS MEDICAL95.17%ENOVEnovis98.45%ESTAEstablishment Labs72.91%MYGNMyriad Genetics99.02%Insider OwnershipCompanyInsider OwnershipAVNSAVANOS MEDICAL2.64%ENOVEnovis2.70%ESTAEstablishment Labs11.09%MYGNMyriad Genetics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAVANOS MEDICAL2,22746.24 million45.02 millionOptionableENOVEnovis7,36757.12 million55.58 millionOptionableESTAEstablishment Labs1,01828.92 million25.61 millionOptionableMYGNMyriad Genetics2,70092.18 million90.24 millionOptionableESTA, AVNS, ENOV, and MYGN HeadlinesRecent News About These CompaniesMyriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Assenagon Asset Management S.A.June 19, 2025 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives $14.38 Consensus PT from AnalystsJune 18, 2025 | americanbankingnews.comShould You Hold Myriad Genetics Stock in Your Portfolio Right Now?June 16, 2025 | zacks.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of "Hold" from BrokeragesJune 15, 2025 | marketbeat.com3 Reasons to Avoid MYGN and 1 Stock to Buy InsteadJune 6, 2025 | msn.comMyriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?June 5, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 86,973 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)June 5, 2025 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Stock Holdings Cut by Jane Street Group LLCJune 5, 2025 | marketbeat.comBalancing Optimism and Caution: Hold Rating for Myriad Genetics Amid Strategic Shifts and UncertaintiesJune 5, 2025 | tipranks.comMyriad Genetics Shares Higher on Prenatal Screen UpdateJune 4, 2025 | marketwatch.comMyriad Genetics Announces Early Access to the FirstGene Multiple Prenatal ScreenJune 3, 2025 | globenewswire.comMyriad Genetics, Inc. (NASDAQ:MYGN) Short Interest Up 41.7% in MayJune 2, 2025 | marketbeat.comMyriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer TypesJune 2, 2025 | finance.yahoo.comWellington Management Group LLP Decreases Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)May 30, 2025 | marketbeat.comVoloridge Investment Management LLC Makes New $1.64 Million Investment in Myriad Genetics, Inc. (NASDAQ:MYGN)May 30, 2025 | marketbeat.comMyriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025May 27, 2025 | insidermonkey.comMyriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025May 27, 2025 | msn.comMyriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comLevi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities FraudMay 27, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities InvestigationMay 27, 2025 | accessnewswire.comSpotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1May 27, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthDarden Stock Set to Sizzle After Blowout Q4 and $1B BuybackBy Thomas Hughes | June 23, 2025View Darden Stock Set to Sizzle After Blowout Q4 and $1B BuybackESTA, AVNS, ENOV, and MYGN Company DescriptionsAVANOS MEDICAL NYSE:AVNS$12.09 -0.05 (-0.41%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$12.11 +0.02 (+0.17%) As of 06/23/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Enovis NYSE:ENOV$30.01 -0.10 (-0.34%) Closing price 06/23/2025 03:59 PM EasternExtended Trading$29.96 -0.05 (-0.17%) As of 06/23/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Establishment Labs NASDAQ:ESTA$36.58 -1.23 (-3.25%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$36.60 +0.02 (+0.05%) As of 06/23/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.Myriad Genetics NASDAQ:MYGN$4.86 -0.06 (-1.22%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$5.16 +0.30 (+6.17%) As of 06/23/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
